-
1.发明授权公开(公告)号：US09650334B2
公开(公告)日：2017-05-16
申请号：US14215533
申请日：2014-03-17
Applicant: AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
Inventor： Wilhelm Amberg , Frauke Pohlki , Udo Lange , Ying X. Wang , Hongyu H. Zhao , Huan-Qiu Li , Jason T. Brewer , Irini Zanze , Justin Dietrich , Anil Vasudevan , Stevan W. Djuric , Yanbin Lao , Charles W. Hutchins
IPC: A61K31/4025 , A61K31/44 , A61K31/4178 , C07D207/09 , C07D403/12 , C07D401/12 , C07D207/48 , C07D401/14 , C07D403/14 , C07D405/14 , C07D487/10 , C07D417/14 , C07D409/14 , C07D495/04 , C07D471/04 , C07D487/04
CPC classification number: C07D207/09 , A61K31/4025 , A61K31/44 , C07D207/48 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/10 , C07D495/04
Abstract: The present invention relates to pyrrolidine derivatives of the formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.
-
2.发明申请公开(公告)号：US20140275086A1
公开(公告)日：2014-09-18
申请号：US14215533
申请日：2014-03-17
Applicant: AbbVie Inc. , AbbVie Deutschland GmbH & Co. KG
Inventor： Wilhelm Amberg , Frauke Pohlki , Udo Lange , Ying X. Wang , Hongyu H. Zhao , Huan-Qiu Li , Jason T. Brewer , Irini Zanze , Justin Dietrich , Anil Vasudevan , Stevan W. Djuric , Yanbin Lao , Charles W. Hutchins
IPC: C07D207/09 , C07D401/12 , C07D207/48 , C07D401/14 , C07D403/14 , C07D487/04 , C07D487/10 , C07D417/14 , C07D409/14 , C07D495/04 , C07D471/04 , C07D403/12 , C07D405/14
CPC classification number: C07D207/09 , A61K31/4025 , A61K31/44 , C07D207/48 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/10 , C07D495/04
Abstract: The present invention relates to pyrrolidine derivatives of the formula (I), or a physiologically tolerated salt thereof.The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.
-
Patent Agency Ranking
公开(公告)号：US09957274B2
公开(公告)日：2018-05-01
申请号：US15588398
申请日：2017-05-05
Applicant: AbbVie Inc.
Inventor： Michael R. Michaelides , Michael L. Curtin , Huan-Qiu Li , Marina A Pliushchev , Ying Wang , Hongyu H. Zhao , Richard F. Clark , Alan S. Florjancic , Zhiqin Ji , Mariazel Torrent , Ramzi F. Sweis , Anil Vasudevan , Justin D. Dietrich
IPC: C07D207/14 , A61K31/40 , C07D487/04 , C07D403/10 , C07D405/04 , C07D413/10 , C07D403/12 , C07D401/12 , C07D403/04 , C07D403/14 , C07D417/14 , C07D471/04 , C07D401/04 , C07D401/14
CPC classification number: C07D487/04 , A61K31/40 , C07D207/14 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/04 , C07D413/10 , C07D417/14 , C07D471/04
Abstract: Compounds having a structure of Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein A1, A2, A3, A4, A5, n, and m are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various EED-related conditions or diseases, including cancer, by administration of such compounds are also provided.
-
4.发明授权Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy 有权异二氢吲哚衍生物，含有它们的药物组合物及其在治疗中的应用公开(公告)号：US09365512B2
公开(公告)日：2016-06-14
申请号：US13764454
申请日：2013-02-11
Applicant: AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
Inventor： Wilhelm Amberg , Udo Lange , Michael Ochse , Frauke Pohlki , Charles W. Hutchins , Irini Zanze , Hongyu H. Zhao , Huan-Qiu Li , Ying X. Wang
IPC: C07D403/12 , C07D209/46 , C07D405/14 , C07D209/44
CPC classification number: C07D209/46 , C07D209/44 , C07D403/12 , C07D405/14
Abstract: The present invention relates to isoindoline derivatives of the formula (I) or a physiologically tolerated salt thereof. The present invention also relates to pharmaceutical compositions comprising such isoindoline derivatives, and the use of such isoindoline derivatives for therapeutic purposes.
Abstract translation: 本发明涉及式（I）的异二氢吲哚衍生物或其生理上耐受的盐。 本发明还涉及包含这种异二氢吲哚衍生物的药物组合物，以及用于治疗目的的这种异吲哚啉衍生物的用途。
-
公开(公告)号：US20170320880A1
公开(公告)日：2017-11-09
申请号：US15588398
申请日：2017-05-05
Applicant: AbbVie Inc.
Inventor： Michael R. Michaelides , Michael L. Curtin , Huan-Qiu Li , Marina A. Pliushchev , Ying Wang , Hongyu H. Zhao , Richard F. Clark , Alan S. Florjancic , Zhiqin Ji , Mariazel Torrent , Ramzi F. Sweis , Anil Vasudevan , Justin D. Dietrich
IPC: C07D487/04 , C07D417/14 , C07D413/10 , C07D405/04 , C07D403/14 , C07D403/12 , C07D403/10 , C07D403/04 , C07D401/14 , C07D401/12 , C07D401/04 , C07D471/04 , C07D207/14
CPC classification number: C07D487/04 , A61K31/40 , C07D207/14 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/04 , C07D413/10 , C07D417/14 , C07D471/04
Abstract: Compounds having a structure of Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein A1, A2, A3, A4, A5, n, and m are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various EED-related conditions or diseases, including cancer, by administration of such compounds are also provided.
-
6.发明授权公开(公告)号：US09656955B2
公开(公告)日：2017-05-23
申请号：US14216222
申请日：2014-03-17
Applicant: AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
Inventor： Wilhelm Amberg , Frauke Pohlki , Udo Lange , Ying X. Wang , Hongyu H. Zhao , Huan-Qiu Li , Jason T. Brewer , Irini Zanze , Justin Dietrich , Anil Vasudevan , Stevan W. Djuric , Yanbin Lao , Charles W. Hutchins
IPC: A61K31/4025 , A61K31/44 , A61K31/4178 , C07D207/09 , C07D403/12 , C07D401/12 , C07D207/48 , C07D401/14 , C07D403/14 , C07D405/14 , C07D487/10 , C07D417/14 , C07D409/14 , C07D495/04 , C07D471/04 , C07D487/04
CPC classification number: C07D207/48 , A61K31/4025 , A61K31/4178 , A61K31/44 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14
Abstract: The present invention relates to pyrrolidine derivatives of the formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.
-
7.发明申请PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY 有权吡咯烷衍生物，含有它们的药物组合物及其在治疗中的使用公开(公告)号：US20140275087A1
公开(公告)日：2014-09-18
申请号：US14216222
申请日：2014-03-17
Applicant: AbbVie Inc. , AbbVie Deutschland GmbH & Co. KG
Inventor： Wilhelm Amberg , Frauke Pohlki , Udo Lange , Ying X. Wang , Hongyu H. Zhao , Huan-Qiu Li , Jason T. Brewer , Irini Zanze , Justin Dietrich , Anil Vasudevan , Stevan W. Djuric , Yanbin Lao , Charles W. Hutchins
IPC: C07D207/48 , C07D403/14 , C07D401/14 , C07D403/12 , C07D401/12
CPC classification number: C07D207/48 , A61K31/4025 , A61K31/4178 , A61K31/44 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14
Abstract: The present invention relates to pyrrolidine derivatives of the formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.
Abstract translation: 本发明涉及式（I）的吡咯烷衍生物或其生理上耐受的盐。 本发明涉及包含这种吡咯烷衍生物的药物组合物以及这种吡咯烷衍生物用于治疗目的的用途。 吡咯烷衍生物是GlyT1抑制剂。
-
-
-
-
-
-
Search Results
7
records
(took 0.058 seconds)
